Insider Transactions Reported by 21 Insiders of X4 Pharmaceuticals, Inc

Symbol
XFOR on Nasdaq
Location
Boston, MA

Insiders trading volume in the past year

X4 Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Paula Ragan President and CEO, Director $1,515,173 12 Feb 2025
Adam R. Craig Executive Chairman, Director $1,090,652 +$249,997 +30% 29 Oct 2025
John Volpone President $550,773 29 Oct 2025
Mary DiBiase Chief Operating Officer $518,005 12 Feb 2025
Christophe Arbet-Engels Chief Medical Officer $392,350 12 Feb 2025
Adam S. Mostafa Chief Financial Officer $385,900 12 Feb 2025
David Kirske Chief Financial Officer $367,182 29 Oct 2025
Arthur Taveras Chief Scientific Officer $218,459 04 Oct 2024
Derek M. Meisner Chief Legal Officer $130,640 17 Aug 2022
Diego Cadavid Chief Medical Officer $93,696 01 Mar 2022
William Aliski Director $85,241 10 Jun 2024
Alison Frances Lawton Director $85,241 10 Jun 2024
Mark Baldry Chief Commercial Officer $62,886 16 May 2025
Natasha Fay Thoren Chief Legal Officer $1,797 20 May 2025
Murray Stewart Director $1,497 01 Jan 2026
Keith Woods Director $1,140 09 Jun 2025
Michael S. Wyzga Director $1,055 01 Jan 2026
Gary Bridger Director $897 01 Jan 2026
David W. J. Mcgirr Director $897 09 Jun 2025
Francoise de Craecker Director $897 01 Jan 2026
Rene Russo Director 02 Jun 2021

Recent Insider Transactions by Companies or Individuals for X4 Pharmaceuticals, Inc

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Gary Bridger XFOR Stock Option (right to buy) Award 110,000 0 01 Jan 2026 Direct
Francoise de Craecker XFOR Stock Option (right to buy) Award 110,000 0 01 Jan 2026 Direct
Michael S. Wyzga XFOR Stock Option (right to buy) Award 110,000 0 01 Jan 2026 Direct
Murray Stewart XFOR Stock Option (right to buy) Award 110,000 0 01 Jan 2026 Direct
Adam R. Craig XFOR Stock Option (right to buy) Award 2,329,154 2,329,154 29 Oct 2025 Direct
John Volpone XFOR Stock Option (right to buy) Award 2,329,154 2,329,154 29 Oct 2025 Direct
David Kirske XFOR Stock Option (right to buy) Award 1,552,769 1,552,769 29 Oct 2025 Direct
Adam R. Craig XFOR Common Stock Purchase 29.7% $249,997 $2.90 86,206 376,087 23 Oct 2025 Direct
John Volpone XFOR Common Stock Award 289,881 289,881 14 Aug 2025 Direct
John Volpone XFOR Stock Option (right to buy) Award 529,201 529,201 14 Aug 2025 Direct
Adam R. Craig XFOR Common Stock Award 289,881 289,881 14 Aug 2025 Direct
Adam R. Craig XFOR Stock Option (right to buy) Award 529,201 529,201 14 Aug 2025 Direct
David Kirske XFOR Common Stock Award 193,254 193,254 14 Aug 2025 Direct
David Kirske XFOR Stock Option (right to buy) Award 352,800 352,800 14 Aug 2025 Direct
John Volpone XFOR Stock Option (right to buy) Award 1,609,873 1,609,873 12 Aug 2025 Direct
Adam R. Craig XFOR Stock Option (right to buy) Award 1,609,873 1,609,873 12 Aug 2025 Direct
David Kirske XFOR Stock Option (right to buy) Award 1,073,249 1,073,249 12 Aug 2025 Direct
Murray Stewart XFOR Common Stock Award 23.5% 1,500 7,883 09 Jun 2025 Direct
Francoise de Craecker XFOR Common Stock Award 46.6% 1,500 4,722 09 Jun 2025 Direct
Gary Bridger XFOR Common Stock Award 46.6% 1,500 4,722 09 Jun 2025 Direct
Keith Woods XFOR Common Stock Award 33.3% 1,500 6,000 09 Jun 2025 Direct
David W. J. Mcgirr XFOR Common Stock Award 46.6% 1,500 4,722 09 Jun 2025 Direct
Michael S. Wyzga XFOR Common Stock Award 37% 1,500 5,555 09 Jun 2025 Direct
Natasha Fay Thoren XFOR Common Stock Award 54.4% 3,333 9,462 20 May 2025 Direct
Mark Baldry XFOR Common Stock Award 4.25% 1,032 25,337 16 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.